29.50
0.82%
0.24
After Hours:
29.50
Overview
News
Price History
Option Chain
Financials
Why BAX Down?
Discussions
Forecast
Stock Split
Dividend History
Baxter International Inc stock is traded at $29.50, with a volume of 2.62M.
It is up +0.82% in the last 24 hours and down -10.96% over the past month.
Baxter offers a variety of medical supplies and equipment to providers. From its legacy operations, Baxter sells injectable therapies for use in care settings, including IV pumps, administrative sets, and solutions; nutritional products; and surgical sealants and hemostatic agents. Baxter expanded its portfolio of hospital-focused offerings by acquiring Hillrom in late 2021, which added basic equipment like hospital beds, operating room equipment, and patient monitoring tools to the portfolio. Baxter has signed an agreement to sell its kidney care tools by early 2025.
See More
Previous Close:
$29.26
Open:
$29.28
24h Volume:
2.62M
Relative Volume:
0.66
Market Cap:
$15.06B
Revenue:
$17.28B
Net Income/Loss:
$108.00M
P/E Ratio:
147.50
EPS:
0.2
Net Cash Flow:
$391.00M
1W Performance:
+1.03%
1M Performance:
-10.96%
6M Performance:
-11.04%
1Y Performance:
-22.63%
Baxter International Inc Stock (BAX) Company Profile
Name
Baxter International Inc
Sector
Industry
Phone
(847) 948-2000
Address
ONE BAXTER PKWY, DEERFIELD, IL
Compare BAX with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
BAX
Baxter International Inc
|
29.50 | 15.06B | 17.28B | 108.00M | 391.00M | 0.20 |
ISRG
Intuitive Surgical Inc
|
535.29 | 190.66B | 7.87B | 2.24B | 586.00M | 6.22 |
BDX
Becton Dickinson Co
|
228.46 | 66.26B | 20.18B | 1.71B | 3.07B | 5.94 |
ALC
Alcon Inc
|
84.06 | 41.58B | 9.76B | 1.16B | 665.00M | 2.34 |
RMD
Resmed Inc
|
231.67 | 34.01B | 4.81B | 1.11B | 1.35B | 7.55 |
WST
West Pharmaceutical Services Inc
|
335.56 | 24.30B | 2.88B | 499.60M | 321.60M | 6.74 |
Baxter International Inc Stock (BAX) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Jul-15-24 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
May-30-24 | Initiated | Goldman | Neutral |
May-10-24 | Downgrade | TD Cowen | Buy → Hold |
May-30-23 | Resumed | Morgan Stanley | Equal-Weight |
Mar-29-23 | Initiated | UBS | Neutral |
Jan-06-23 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
Jan-05-23 | Downgrade | Raymond James | Outperform → Mkt Perform |
Jan-03-23 | Downgrade | BofA Securities | Buy → Neutral |
Dec-19-22 | Downgrade | JP Morgan | Overweight → Neutral |
Dec-15-22 | Downgrade | Deutsche Bank | Buy → Hold |
Dec-12-22 | Downgrade | Citigroup | Buy → Neutral |
Oct-18-22 | Initiated | Barclays | Overweight |
Oct-12-22 | Initiated | Jefferies | Hold |
Jun-24-22 | Downgrade | Wells Fargo | Overweight → Equal Weight |
Apr-04-22 | Downgrade | Goldman | Neutral → Sell |
Mar-02-22 | Resumed | BofA Securities | Buy |
Feb-18-22 | Reiterated | KeyBanc Capital Markets | Overweight |
Feb-18-22 | Reiterated | Morgan Stanley | Overweight |
Feb-18-22 | Reiterated | Raymond James | Outperform |
Feb-18-22 | Reiterated | Stifel | Buy |
Feb-18-22 | Reiterated | UBS | Neutral |
Feb-18-22 | Reiterated | Wells Fargo | Overweight |
Feb-11-22 | Initiated | Goldman | Neutral |
Jan-07-22 | Resumed | Citigroup | Buy |
Jan-07-22 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
Sep-13-21 | Upgrade | Cowen | Market Perform → Outperform |
Sep-03-21 | Upgrade | Barclays | Equal Weight → Overweight |
May-25-21 | Initiated | Barclays | Equal Weight |
Jan-29-21 | Downgrade | Piper Sandler | Overweight → Neutral |
Jan-06-21 | Downgrade | UBS | Buy → Neutral |
Dec-15-20 | Downgrade | Goldman | Buy → Neutral |
Oct-01-20 | Upgrade | Citigroup | Neutral → Buy |
Sep-04-20 | Downgrade | Argus | Buy → Hold |
Jun-24-20 | Initiated | Oppenheimer | Outperform |
Mar-19-20 | Upgrade | Stifel | Hold → Buy |
Mar-18-20 | Upgrade | KeyBanc Capital Markets | Sector Weight → Overweight |
Mar-05-20 | Initiated | Citigroup | Neutral |
Feb-13-20 | Initiated | Goldman | Buy |
Jan-02-20 | Upgrade | Evercore ISI | In-line → Outperform |
Dec-17-19 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
Jun-26-19 | Initiated | KeyBanc Capital Markets | Sector Weight |
Apr-08-19 | Downgrade | Evercore ISI | Outperform → In-line |
Jan-02-19 | Upgrade | Citigroup | Neutral → Buy |
Jan-02-19 | Upgrade | Morgan Stanley | Underweight → Overweight |
Nov-02-18 | Upgrade | Argus | Hold → Buy |
Oct-16-18 | Initiated | Barclays | Underweight |
May-17-18 | Resumed | Piper Jaffray | Overweight |
Feb-06-18 | Reiterated | Citigroup | Neutral |
Jan-03-18 | Initiated | Evercore ISI | Outperform |
Jan-03-18 | Upgrade | Raymond James | Mkt Perform → Outperform |
View All
Baxter International Inc Stock (BAX) Latest News
Baxter International Inc. stock rises Friday, still underperforms market - MarketWatch
Centre Asset Management LLC Sells 21,904 Shares of Baxter International Inc. (NYSE:BAX) - MarketBeat
Hurricane Helene impact on Baxter to further limit IV fluid supply, HHS says - AOL
Baxter International Inc. (NYSE:BAX) Short Interest Up 6.1% in December - MarketBeat
Earnings Review and Free Research Report: Baxter’s Revenue Grew 6%; EPS Rocketed 96% - AccessWire
BAXTER SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Baxter International In - AccessWire
How Is Baxter International's Stock Performance Compared to Other Medical Devices Stocks? - MSN
Investors in Baxter International (NYSE:BAX) have unfortunately lost 64% over the last three years - Simply Wall St
Early Alert: Solution Set Issue from Baxter Healthcare Corporation - FDA.gov
Baxter International (NYSE:BAX) Sets New 52-Week LowWhat's Next? - MarketBeat
Baxter stock touches 52-week low at $28.6 amid market challenges - Investing.com Australia
Should We Be Cautious About Baxter International Inc.'s (NYSE:BAX) ROE Of 1.6%? - Yahoo Finance
Prolotherapy Market Overall Study Report 2024-2031 | Pfizer - openPR
Baxter International Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
Golden Valley office, contender for Baxter Healthcare R&D site, sold for $19.7M - The Business Journals
Baxter International Inc. (BAX): Among the Biggest Dividend Cuts and Suspensions of 2024 - Insider Monkey
10 Biggest Dividend Cuts and Suspensions of 2024 - Insider Monkey
Page 2 | Baxter International Inc. Trade Ideas — LS:853815 - TradingView
Baxter International Sees Unusually Large Options Volume (NYSE:BAX) - MarketBeat
Baxter International Inc. stock outperforms competitors despite losses on the day - MarketWatch
Baxter Resumes Production of Peritoneal Dialysis Solutions - DocWire News
Interesting BAX Put And Call Options For August 2025 - Nasdaq
Baxter International Inc. (NYSE:BAX) Given Consensus Recommendation of "Hold" by Analysts - MarketBeat
Baxter International Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Baxter stock hits 52-week low at $29.14 amid market challenges - Investing.com Australia
Baxter International CEO to Present at J.P. Morgan Healthcare Conference 2025 - StockTitan
Parenteral Nutrition Market May Set Epic Growth Story | Baxter, Hospira, Pfizer - openPR
Baxter International Inc. stock outperforms competitors on strong trading day - MarketWatch
Baxter International's SWOT analysis: medical supplies stock faces mixed signals - Investing.com
Baxter International Inc. stock underperforms Monday when compared to competitors - MarketWatch
Baxter International (NYSE:BAX) Hits New 1-Year LowTime to Sell? - MarketBeat
Toronto Dominion Bank Buys 22,787 Shares of Baxter International Inc. (NYSE:BAX) - MarketBeat
Fresenius Can't Stop Baxter's Effort To Save Dialysis Patent - Law360
Baxter Stock May Gain Following Five New Injectable Product Launches - Yahoo Finance
Geode Capital Management LLC Grows Holdings in Baxter International Inc. (NYSE:BAX) - MarketBeat
Advanced Wound Care Management Market Share to Rise At 5.1% CAGR, To Reach USD 17.50 Billion by 2034 | PMR - GlobeNewswire Inc.
Baxter International Inc Stock (BAX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):